Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains
暂无分享,去创建一个
Alberto Rábano | C. Hillard | E. J. Carrier | A. Rábano | J. Romero | Cecilia J Hillard | Cristina Benito | Estefanía Núñez | Rosa M Tolón | Erica J Carrier | Julián Romero | C. Benito | R. Tolón | E. Núñez | E. Núñez
[1] K. Mackie,et al. Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.
[2] P. Zandi,et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.
[3] Tony Wyss-Coray,et al. Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.
[4] T. Freund,et al. Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] T. Möller,et al. Astrocytes in Culture Produce Anandamide and Other Acylethanolamides* , 2002, The Journal of Biological Chemistry.
[6] M. Calero,et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. , 2002, Brain research. Molecular brain research.
[7] J. Ramos,et al. Endocannabinoids and basal ganglia functionality. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[8] E. Monti,et al. Endocannabinoids in the immune system and cancer. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[9] D. Deutsch,et al. The fatty acid amide hydrolase (FAAH). , 2000, Prostaglandins, leukotrienes, and essential fatty acids.
[10] Patrick R Hof,et al. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. , 2002, Progress in brain research.
[11] G. Cabral,et al. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. , 2002, International immunopharmacology.
[12] A. Hofman,et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.
[13] D. Piomelli,et al. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. , 2001, The Journal of pharmacology and experimental therapeutics.
[14] C. Breivogel,et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.
[15] C. Felder,et al. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. , 2001, Pharmacology & therapeutics.
[16] D. Deutsch,et al. The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase* , 2001, The Journal of Biological Chemistry.
[17] R. Strohmeyer,et al. Molecular and cellular mediators of Alzheimer's disease inflammation. , 2001, Journal of Alzheimer's disease : JAD.
[18] D. Piomelli,et al. Carrier‐mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‐arachidonylglycerol , 2000, Neuroreport.
[19] D. Giulian. Microglia and the immune pathology of Alzheimer disease. , 1999, American journal of human genetics.
[20] G. Cabral,et al. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.
[21] K. Mackie,et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.
[22] M. Elphick,et al. A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[23] D. Deutsch,et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry , 1998, Neuroscience Letters.
[24] W. Campbell,et al. Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. , 1998, The Journal of pharmacology and experimental therapeutics.
[25] F. Berrendero,et al. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35s]guanylyl-5′-O-(thio)-triphosphate binding in the basal ganglia of aged rats , 1998, Neuroscience.
[26] J. Sutcliffe,et al. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system , 1997, Journal of neuroscience research.
[27] R. Faull,et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.
[28] R. Pertwee. Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.
[29] A. Buriani,et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] T. Bisogno,et al. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’ , 1995, FEBS letters.
[31] S. Galiègue,et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.
[32] C. Clark,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1990, Neurology.
[33] M. Herkenham,et al. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.
[34] M. Herkenham,et al. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus , 1994, Annals of neurology.
[35] M. Herkenham,et al. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.
[36] R. Faull,et al. Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.
[37] J. Vanderhaeghen,et al. Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum , 1992, Neuroscience Letters.
[38] J. Vanderhaeghen,et al. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry , 1992, Neuroscience.
[39] M. Herkenham,et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[40] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.